Optimization of a Potent, Orally Active S1P1 Agonist Containing a Quinolinone Core
ACS Medicinal Chemistry Letters2011Vol. 3(1), pp. 74–78
Citations Over TimeTop 25% of 2011 papers
Paul E. Harrington, Michael D. Croghan, Christopher Fotsch, Mike Frohn, Brian A. Lanman, Lewis D. Pennington, Alexander J. Pickrell, Anthony B. Reed, Kelvin Sham, Andrew S. Tasker, Heather A. Arnett, Michael Fiorino, Matthew R. Lee, Michele McElvain, Henry Morrison, Han Xu, Yang Xu, Xuxia Zhang, Min Wong, Victor J. Cee
Abstract
The optimization of a series of S1P1 agonists with limited activity against S1P3 is reported. A polar headgroup was used to improve the physicochemical and pharmacokinetic parameters of lead quinolinone 6. When dosed orally at 1 and 3 mg/kg, the azahydroxymethyl analogue 22 achieved statistically significant lowering of circulating blood lymphocytes 24 h postdose. In rats, a dose-proportional increase in exposure was measured when 22 was dosed orally at 2 and 100 mg/kg.
Related Papers
- → Pharmacokinetics of (−)-epicatechin in rabbits(2009)11 cited
- → Pharmacokinetics of ketoprofen enantiomers in monkeys following single and multiple oral administration(1994)21 cited
- [The pharmacokinetics of rhein in 12 healthy volunteers after oral administration of rhubarb extract].(2005)
- Study on pharmacokinetics of Norfloxacin in carp following different forms administration(2000)